Laparoscopic Hepatectomy Versus Microwave Ablation for Multifocal 3-5 cm Hepatocellular Carcinoma: a Multi-centre, Real-world Study

Overview

Journal Int J Surg

Specialty General Surgery

Date 2024 Dec 19

PMID 39699863

Authors

Zhen Wang

Chuan Pang

Qiong Meng

De-Zhi Zhang

Zhi-Xian Hong

Guang-Bin He

Hong Yang

Bang-De Xiang

Xiao Li

Tian-An Jiang

Kai Li

Zhe Tang

Fei Huang

Man Lu

Xiao-Ling Yu

Zhi-Gang Cheng

Fang-Yi Liu

Zhi-Yu Han

Jian-Ping Dou

Song-Song Wu

Jie Yu

Ping Liang

Affiliations

Soon will be listed here.

Abstract

Background: Researches comparing laparoscopic liver resection (LLR) with microwave ablation (MWA) for 3-5 cm multifocal hepatocellular carcinoma (MFHCC) are rare.

Materials And Methods: From 2008 to 2019, 666 intrahepatic tumours in 289 patients from 12 tertiary medical centres in China were included in this retrospective study. Propensity score matching (PSM) was performed to balance variables between the two treatment groups over time frames 2008-2019 and 2013-2019 to observe the potential impact of advancements in intervention techniques on overall survival (OS), disease-free progression (DFS) of patients. complications, hospitalization, and cost were compared.

Results: Among 289 patients, the median age was 59 years [interquartile range (IQR) 52-66]. 2008-2019, after PSM, the median OS was 97.4 months in the LLR group and 75.2 months (95% CI 47.8-102.6) in the MWA group during a follow-up period of 39.0 months. The 1-year, 3-year and 5-year OS rates in the two groups were 91.8%, 72.6%, 60.7% and 96.5%, 72.8%, 62.5% [hazard ratio (HR) 1.03, 95% CI 0.62-1.69, P =0.920]; The corresponding DFS rates were 75.9%, 57.2%, 46.9%, and 53.1%, 17.5%, 6.2% (HR 0.35, 95% CI 0.23-0.54, P <0.001). 2013-2019, the median OS time was not reached in either group during the 34.0 months of follow-up, the 1-year, 3-year and 5-year OS rates in the two groups were 90.2%, 67.6%, 56.7% and 96.5%, 76.7%, 69.7% (HR 1.54, 95% CI 0.79-3.01, P =0.210); The corresponding DFS rates were 69.6%, 53.9%, 43.3%, and 70.4%, 32.1%, 16.5% (HR 0.68, 95% CI 0.41-1.11, P =0.120). The incidence of major complications was similar in both groups (all P> 0.05). MWA had shorter intervention times, hospitalization, and lower costs.

Conclusions: For resectable MFHCC patients, LLR is preferable due to its lower recurrence rate. For patients who do not qualify for LLR, advances in ablation technology have promoted MWA as a promising alternative.

References

Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J . Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 2003; 129(1):43-51. DOI: 10.1007/s00432-002-0396-4. View

Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N . Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006; 26(6):680-7. DOI: 10.1111/j.1478-3231.2006.001285.x. View

Tsilimigras D, Mehta R, Paredes A, Moris D, Sahara K, Bagante F . Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria. Ann Surg. 2020; 272(4):574-581. DOI: 10.1097/SLA.0000000000004346. View

Martinez-Cecilia D, Cipriani F, Shelat V, Ratti F, Tranchart H, Barkhatov L . Laparoscopic Versus Open Liver Resection for Colorectal Metastases in Elderly and Octogenarian Patients: A Multicenter Propensity Score Based Analysis of Short- and Long-term Outcomes. Ann Surg. 2017; 265(6):1192-1200. DOI: 10.1097/SLA.0000000000002147. View

Wang H, Feng L, Qian Y, Cao Z, Wu M, Cong W . Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior?. Ann Transl Med. 2019; 7(18):428. PMC: 6803243. DOI: 10.21037/atm.2019.08.114. View

Yang S, Luo Y, Chen M, Zhou Y, Lu F, Deng D . A systematic review and meta-analysis comparing the prognosis of multicentric occurrence and vs. intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy. HPB (Oxford). 2017; 19(10):835-842. DOI: 10.1016/j.hpb.2017.06.002. View

Soubrane O, Goumard C, Laurent A, Tranchart H, Truant S, Gayet B . Laparoscopic resection of hepatocellular carcinoma: a French survey in 351 patients. HPB (Oxford). 2013; 16(4):357-65. PMC: 3967888. DOI: 10.1111/hpb.12142. View

Llovet J, Bruix J . Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000; 32(3):679-80. DOI: 10.1053/jhep.2000.16475. View

Kim P, Jang J, Atenafu E, Fischer S, Greig P, McGilvray I . Outcomes after hepatic resection and subsequent multimodal treatment of recurrence for multifocal hepatocellular carcinoma. Br J Surg. 2013; 100(11):1516-22. DOI: 10.1002/bjs.9263. View

10.

Aufhauser Jr D, Sadot E, Murken D, Eddinger K, Hoteit M, Abt P . Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy. Ann Surg. 2017; 267(5):922-928. PMC: 5507755. DOI: 10.1097/SLA.0000000000002135. View

11.

Wang B, Xia C, Lau W, Lu X, Dong H, Yu W . Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery. J Am Coll Surg. 2013; 217(6):1054-62. DOI: 10.1016/j.jamcollsurg.2013.07.402. View

12.

Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N . Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2011; 56(4):886-92. DOI: 10.1016/j.jhep.2011.10.021. View

13.

Wang Z, Liu M, Zhang D, Wu S, Hong Z, He G . Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC. Hepatology. 2022; 76(1):66-77. DOI: 10.1002/hep.32323. View

14.

Wen T, Jin C, Facciorusso A, Donadon M, Han H, Mao Y . Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr. 2018; 7(5):353-371. PMC: 6230838. DOI: 10.21037/hbsn.2018.08.01. View

15.

Brown K . Liver transplantation. Curr Opin Gastroenterol. 2005; 21(3):331-6. DOI: 10.1097/01.mog.0000159830.36793.2b. View

16.

Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J . Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2016; 65(1):310-335. DOI: 10.1002/hep.28906. View

17.

Wei R, Huang G, Zhang M, Li B, Zhang H, Shi M . Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin Cancer Res. 2013; 19(17):4780-91. DOI: 10.1158/1078-0432.CCR-12-2728. View

18.

Nathan H, Hyder O, Mayo S, Hirose K, Wolfgang C, Choti M . Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg. 2013; 258(6):1022-7. PMC: 3994667. DOI: 10.1097/SLA.0b013e31827da749. View

19.

Zhang P, Wei C, Huang X, Peng R, Yang X, Lu J . Circular RNA circTRIM33-12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression. Mol Cancer. 2019; 18(1):105. PMC: 6545035. DOI: 10.1186/s12943-019-1031-1. View

20.

Li J, Zhou J, Yang P, Xia Y, Shi Y, Wu D . Nomograms for survival prediction in patients undergoing liver resection for hepatitis B virus related early stage hepatocellular carcinoma. Eur J Cancer. 2016; 62:86-95. DOI: 10.1016/j.ejca.2016.04.011. View